| __timestamp | Takeda Pharmaceutical Company Limited | Viatris Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 612613000000 | 1499100000 |
| Thursday, January 1, 2015 | 650773000000 | 1923500000 |
| Friday, January 1, 2016 | 619061000000 | 2351400000 |
| Sunday, January 1, 2017 | 628106000000 | 2564000000 |
| Monday, January 1, 2018 | 717599000000 | 2397300000 |
| Tuesday, January 1, 2019 | 964737000000 | 2503400000 |
| Wednesday, January 1, 2020 | 875663000000 | 3344600000 |
| Friday, January 1, 2021 | 886361000000 | 4529200000 |
| Saturday, January 1, 2022 | 997309000000 | 4179100000 |
| Sunday, January 1, 2023 | 1053819000000 | 4650100000 |
| Monday, January 1, 2024 | 1053819000000 |
Data in motion
In the ever-evolving pharmaceutical industry, understanding the financial dynamics of major players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Takeda Pharmaceutical Company Limited and Viatris Inc. from 2014 to 2023. Over this period, Takeda's SG&A expenses have shown a significant upward trend, increasing by approximately 72% from 2014 to 2023. In contrast, Viatris Inc. has experienced a more modest growth of around 210% in the same timeframe. Notably, Takeda's expenses peaked in 2023, reaching over 1 trillion yen, while Viatris's expenses were just shy of 5 billion dollars. This disparity highlights the scale and operational differences between the two companies. However, the data for 2024 is incomplete, indicating potential changes in the financial landscape. Such insights are invaluable for investors and industry analysts alike.
Regeneron Pharmaceuticals, Inc. or Viatris Inc.: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Takeda Pharmaceutical Company Limited vs Ionis Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs CymaBay Therapeutics, Inc.
Who Optimizes SG&A Costs Better? United Therapeutics Corporation or Viatris Inc.
Breaking Down SG&A Expenses: Incyte Corporation vs Viatris Inc.
Viatris Inc. or Bio-Techne Corporation: Who Manages SG&A Costs Better?
Viatris Inc. and Sarepta Therapeutics, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Viatris Inc. and Verona Pharma plc
Cost Management Insights: SG&A Expenses for Viatris Inc. and Catalyst Pharmaceuticals, Inc.
Comparing SG&A Expenses: Viatris Inc. vs Amicus Therapeutics, Inc. Trends and Insights
Comparing SG&A Expenses: Viatris Inc. vs Agios Pharmaceuticals, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Viatris Inc. and Viridian Therapeutics, Inc.